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clinical response rate is genotype speciﬁc in chronic infec-
tions, even after accounting for host factors such as sex,
age, degree of ﬁbrosis and ethnicity. The difference in clin-
ical response rates among HCV genotypes has yet to be
explained. Because HCV genotypes likely diverged hundreds
of years ago, viral elements that confer clinical resistance
would be relatively ancient and subsequently conserved by
natural selection.
Methods: We used the full-length genome sequences of
all 346 full-length HCV genomic sequences to perform a com-
prehensive, rigorous phylogenetic analysis using distance,
maximum likelihood and parsimony-based optimality crite-
ria. We then used the robust phylogeny as a template for
mapping clinical resistance data and inferring an evolution-
ary pattern of genotype speciﬁc change. In addition, we used
character reconstruction methods to infer sequence changes
that correlate with changing resistance. We also applied
population genetic methods to infer the relative ages of HCV
genotypes for comparison with our phylogenetic methods.
Results: The phylogeny that resulted from our analyses,
depicting the evolutionary history of HCV and the relative
branching order of each of the major genotypes, shows a
trend toward increasing interferon resistance as each new
genotype diverged from a common ancestral lineage. We
identiﬁed several key amino acid residues that may be
responsible for increasing interferon therapy resistance.
Conclusion: Our results suggest that the branching age of
each genotype is predictive of the relative rates of response
to therapy. The apparent paradox of how the modern ther-
apy of interferon injections could select for an ancient,
adaptive trait, may be explained by ancient selective pres-
sure from natural innate immune systems.
doi:10.1016/j.ijid.2008.05.1248
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Background: The role of Hepatitis G Virus (HGV) in the
pathogenesis of chronic liver disease has long been debated.
HGV positivity has been reported at varying rates from
around the world; however, there is insufﬁcient data regard-
ing co-infection status and prevalence in our part of the
world. Hence, the primary objective of this study was to
determine the prevalence of HGV among chronic liver dis-
ease (CLD) patients and apparently healthy voluntary blood
donors in Kerala. The secondary objective was to evaluate
the co-infection status of HGV along with HBV and/or HCV.
Methods: The study group consisted of 60 serum samples
of which 26 were from patients with chronic liver disease and
34 from healthy voluntary blood donors. Viral RNA isolated
from the serum samples was ampliﬁed and tested for HGV
by nested RT-PCR using primers. The positive samples were
subjected to RFLP analysis and sequencing of amplicons to
conﬁrm the presence of HGV RNA. The HBV/HCV positivity
of all samples were collected and compared with HGV RNA
positivity to establish co-infection status
Results: Out of 60 samples studied, 28 (46.7%) were pos-
itive for HGV RNA. Between the study groups, CLD patients
exhibited higher prevalence (50%) compared to the volun-
tary blood donors (44%). Co-infection of HGV with HBV/HCV
was more among the CLD patients (61.5%) as compared to
voluntary blood donors (36.3%) whereas isolated HGV infec-
tion was more common in the voluntary blood donor group
(58.3%) as compared to CLD patients (38.4%). Among the
CLD patients, HGV positivity was observed in 71.4% of the
HCV positive samples compared to 50% of the HBV positive
samples.
Conclusion: Our study reports a higher incidence of HGV
RNA positivity among both CLD patients and voluntary blood
donors in Kerala as compared to reports from other parts
of India. The study also reﬂects a higher incidence of HGV
co-infection with HCV/HBV among the CLD patients as com-
pared to a higher rate of isolated HGV infection among
apparently healthy voluntary blood donors. These observa-
tions probably point to a role for HGV in increasing the risk
for chronic liver disease as a co-infection though it may not
be a causative agent on its own.
doi:10.1016/j.ijid.2008.05.1249
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Background and aim: Chronic infection of hepatitis C
virus (HCV) may lead to hepatic ﬁbrosis and the precise
mechanisms remain unclear.
Methods: In this study, hepatic stellate cells (HSC) were
transiently transfected with a HCV E2-expression vector and
subjected to semi-quantitative RT-PCR and western blotting
to see the impact of E2 protein on the expression levels of
certain molecules involved in ﬁbrogenesis
Results: The expression of E2 protein may promote
the expression of alpha-smooth muscle actin, and colla-
gen alpha(I) in a time-dependent fashion. Furthermore,
mRNA levels of several pro-ﬁbrosis or pro-inﬂammatory
cytokines, including TGF-1, connective tissue growth fac-
tor (CTGF), IL-6 and IL-1, were signiﬁcantly increased in
E2 transfected-HSC cell lines, while the protein level and
activity of MMP-s are also considerably increased.
Conclusion: Taken together, E2 protein may involve in the
hepatic ﬁbrogenesis via an up-regulation of ﬁbrosis-related
proteins.
doi:10.1016/j.ijid.2008.05.1250
